title: Long-term clinical performance of paclitaxel-eluting stents coated with a bioactive polymer (P-5) containing a triflusal derivative: results of the REWAC registry.
abstract: OBJECTIVE
  Although drug-eluting stents have dramatically reduced angiographic restenosis and clinical need for repeat revascularization procedures, some adverse effects, such as late stent thrombosis, have been described. We evaluated clinical performance of paclitaxel-eluting stents coated with a new bioactive polymer system (P-5) based on a copolymer of an acrylic derivative of triflusal in patients with coronary artery disease.
  
  
  RESULTS
  This was a multicenter, observational, prospective study to assess the incidence of target lesion revascularization (TLR) at 6 months and clinical major adverse cardiac events (MACEs) at 1 and 6 months and 1 and 2 years post-stent implantation in 537 patients. After stent implantation, only 1 case of thrombus and acute occlusion was reported in 1 lesion (0.14%). The incidence of new TLR was 0.89% at 6 months, 1.08% at 1 year, and 1.49% at 2 years, with a cumulative incidence of 3.54%. MACEs included cardiac death (0.93%), myocardial infarction (0.37%), and cardiac surgery (0.19%). No cases of late or very late stent thrombosis were recorded.
  
  
  CONCLUSIONS
  Under routine clinical practice, the implantation of paclitaxel-eluting stents coated with P-5 is associated with favorable clinical outcomes in both the short and long term (2 years) in patients with coronary artery disease.
authors.affiliation: Clinica Moncloa, Madrid, Spain.
authors.forename: Eulogio
authors.initials: E
authors.lastname: García
authors.forename: Antoni
authors.initials: A
authors.lastname: Serra
authors.forename: José Javier
authors.initials: JJ
authors.lastname: Zueco
authors.forename: Mariano
authors.initials: M
authors.lastname: Larman
authors.forename: José Ramón
authors.initials: JR
authors.lastname: Rumoroso
authors.forename: José
authors.initials: J
authors.lastname: Moreu
authors.forename: Jordi
authors.initials: J
authors.lastname: Guarinos
authors.forename: María Rosario
authors.initials: MR
authors.lastname: Ortas
authors.forename: Basaganyas
authors.initials: B
authors.lastname: Puigfel
authors.forename: Adolfo
authors.initials: A
authors.lastname: Rincón
authors.forename: Karagounis
authors.initials: K
authors.lastname: Ioannidis
authors.forename: Núria
authors.initials: N
authors.lastname: Piqué
mesh_terms: D000368:Aged; D003324:Coronary Artery Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D011108:Polymers; D011446:Prospective Studies; D012042:Registries; D012459:Salicylates; D013927:Thrombosis / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D011108:Polymers; D012459:Salicylates; C016167:triflusal; D017239:Paclitaxel